Home / Pfizer News: Metsera Acquisition, Financials, Deals, and More

Pfizer News: Metsera Acquisition, Financials, Deals, and More

By: Jasmin Espinas

Updated: October 31, 2025

Published: October 31, 2025

Advertising Disclosure

The content featured in this article may include sponsored placements or affiliate partnerships. These do not reflect the views or recommendations of Financial Daily Update.

We do not guarantee the accuracy or reliability of information presented by third-party contributors or advertisers. You are encouraged to verify all product claims and service terms directly with the provider.

Some of the links on this page may lead to financial partners. If you take action through those links—such as applying for a loan or signing up for a service—we may earn compensation.

That said, all editorial content is written independently and without bias, in line with our mission to provide transparent and informative financial reporting.

Pfizer is one of the largest names in pharmaceuticals. In recent Pfizer news, analysts say the company holds an advantage in the Metsera acquisition over Novo Nordisk.

This article looks at where the Metsera deal fits within Pfizer’s broader strategy. It also covers the company’s latest financials, deals, and outlook.

Pfizer May Have a Strategic Edge in the Metsera Acquisition Battle

Pfizer may have more than financial leverage in its bid for Metsera.

WATCH: Novo Nordisk’s late bid to hijack Pfizer’s takeover of US obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board https://t.co/jaK8DlB2Pf pic.twitter.com/N1PflaWN2Y

— Reuters Business (@ReutersBiz) October 30, 2025

On October 30, Novo Nordisk disclosed a surprise counteroffer for the obesity-focused biotech firm, calling its bid “superior” to the deal Pfizer had already secured.

While Novo’s offer raised the stakes, analysts say Pfizer could use political positioning to tilt the outcome. Bernstein’s Courtney Breen noted the Trump administration tends to support companies with strong U.S. ties or political influence.

Pfizer CEO Albert Bourla has also maintained close contact with the administration, which may prove relevant if regulatory review becomes a factor.

Legal strategy is in the works. Pfizer has indicated it’s prepared to contest Novo’s offer in court, and antitrust concerns could surface.

Pfizer Announces 2025 Fourth-Quarter Dividend

On October 9, Pfizer announced that its board of directors approved a fourth-quarter dividend of $0.43 per share for 2025.

The dividend will be paid on December 1 to shareholders recorded as of the close of business on November 7.

This marks Pfizer’s 348th straight quarterly dividend, reinforcing the company’s long-standing approach to returning capital to shareholders on a consistent schedule.

Pfizer Reaches Landmark Deal to Cut U.S. Drug Prices

In other Pfizer news, the company said it reached a pricing deal with the Trump administration to lower out-of-pocket costs for U.S. patients.

#BreakingNews: Today, Pfizer announced a historic and voluntary agreement with @POTUS that will ensure American patients pay lower prices for their prescription medicines. With this agreement in place, we can invest even more boldly in the U.S. – fueling growth, creating jobs,… pic.twitter.com/XOHQw8XzxI

— Pfizer Inc. (@pfizer_news) September 30, 2025

The agreement meets four specific requests from the White House and includes protections around tariffs and pricing rules.

Pfizer says it will help guide its long-term investment plans in the U.S.

As part of the deal, Pfizer agreed to increase its focus on U.S.-based R&D and shift more manufacturing back to domestic sites.

The company also said the agreement will support its work on cancer drugs, obesity treatments, vaccines, and therapies targeting inflammation and immune conditions.

CEO Albert Bourla joined President Trump and senior officials at the White House to announce the agreement.

Pfizer News: Conclusion

Pfizer is trying to steady its footing after a year of uneven performance. The company is shifting focus toward long-term growth, leaning on its drug pipeline, smaller biotech deals, and new U.S. investments to rebuild momentum.

For investors, the next few quarters will be about execution. Pfizer’s ability to deliver consistent returns while integrating new assets will be key to restoring market confidence.

To keep up with the latest Pfizer news and corporate finance updates in the pharmaceutical industry, subscribe to Financial Daily Update today.